贝伐珠单抗联合FOLFOX化疗方案治疗转移性结肠癌的近期疗效及对肿瘤相关转移基因-1、血管内皮生长因子表达的影响  

Short-term efficacy of bevacizumab combined with FOLFOX chemotherapy regimen in treating metastatic colon cancer and its effect on expressions of tumor metastasis-associated 1 and vascular endothelial growth factor

作　　者：米晶晶 曹鸿鑫 朱咪 MI Jingjing;CAO Hongxin;ZHU Mi(Department of Pharmacy,Yulin No.2 Hospital,Yulin 719000,Shaanxi,China;Department of Oncology Radiotherapy,Yulin No.2 Hospital,Yulin 719000,Shaanxi,China)

机构地区：[1]榆林市第二医院药学部,陕西榆林719000 [2]榆林市第二医院肿瘤放疗科,陕西榆林719000

出　　处：《癌症进展》2021年第19期2012-2015,共4页Oncology Progress

摘　　要：目的探究贝伐珠单抗联合FOLFOX化疗方案治疗转移性结肠癌的近期疗效,并观察不同化疗方案对肿瘤相关转移基因-1(Mta-1)以及血管内皮生长因子(VEGF)表达的影响。方法将80例转移性结肠癌患者按治疗方式不同分为对照组及联合组,每组40例。对照组采用FOLFOX化疗方案,联合组采用FOLFOX化疗方案联合贝伐珠单抗治疗,观察并对比两组患者的近期疗效、疾病进展时间(TTP)、不良反应发生率以及治疗前后Mta-1、VEGF表达的差异。结果两组患者客观有效率和疾病控制率比较,差异均无统计学意义(P﹥0.05)。两组患者高血压、血栓、蛋白尿发生率及不良反应总发生率比较,差异均无统计学意义(P﹥0.05)。治疗后,两组患者Mta-1阳性细胞百分比和VEGF水平均降低(P﹤0.05),且联合组患者Mta-1阳性细胞百分比和VEGF水平均明显低于对照组(P﹤0.01)。对照组患者的中位TTP为13个月,短于联合组患者的24个月,差异有统计学意义(P﹤0.05)。结论贝伐珠单抗联合FOLFOX化疗可有效降低患者Mta-1阳性细胞百分比和VEGF水平,且与FOLFOX化疗方案相比,贝伐珠单抗联合FOLFOX化疗患者的TTP更长,有推广价值。Objective To investigate the short-term efficacy of bevacizumab combined with FOLFOX chemotherapy regimen in treating metastatic colon cancer,and to observe the effect of different chemotherapy regimens on tumor metastasis-associated 1(Mta-1)and vascular endothelial growth factor(VEGF).Method A total of 80 patients with metastatic colon cancer were divided into control group and combined group with 40 cases in each group according to the varying treatment methods.The control group was treated with FOLFOX chemotherapy regimen,and the combined group was given FOLFOX chemotherapy regimen combined with bevacizumab.The short-term efficacy,time to progression(TTP),the incidence of adverse events,and alterations of Mta-1 and VEGF before and after the treatment were observed and compared between the two groups.Result There was no statistically significant difference between the two groups of patients in terms of the objective response rate and disease control rate(P>0.05).There were also no statistically significant differences in the incidence of hypertension,thrombosis,proteinuria,and total adverse events between the two groups(P>0.05).After the treatment,the proportion of Mta-1 positive cells and the levels of VEGF in the two groups of patients decreased(P<0.05),and the proportion of Mta-1 positive cells and the levels of VEGF in the combined group were significantly lower than those in the control group(P<0.01).The median TTP of the control group was 13 months,which was shorter than 24 months in the combined group,the difference was statistically significant(P<0.05).Conclusion Bevacizumab plus FOLFOX chemotherapy could effectively reduce the proportion of Mta-1 positive cells and the level of VEGF in cancer patients.In addition,bevacizumab plus FOLFOX has longer TTP compared with routine FOLFOX chemotherapy,indicating the new regimen has promising promotion value.

关 键 词：贝伐珠单抗 奥沙利铂 转移性结肠癌 肿瘤相关转移基因-1 血管内皮生长因子 

分 类 号：R735.35[医药卫生—肿瘤]